导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.24% | 2255/4773 |
| 近一周 | -1.71% | 666/5462 |
| 近一月 | -3.64% | 1881/5421 |
| 近一季 | -7.82% | 2544/5209 |
| 近半年 | -6.03% | 2997/4920 |
| 近一年 | 2.64% | 2076/4366 |
| 近两年 | 52.40% | 1411/2954 |
| 近三年 | 13.90% | 1661/2253 |
| 成立以来 | 11.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.76% 1949/4961 |
15.96% 1615/5312 |
- - |
- - |
| 2025 | 20.92% 2067/4813 |
4.48% 931/3635 |
-1.59% 3214/4076 |
21.82% 1742/4524 |
-3.46% 3280/4813 |
| 2024 | 1.46% 2010/3463 |
-6.03% 1999/2808 |
-5.41% 1719/3014 |
15.03% 1835/3129 |
-0.77% 1514/3463 |
| 2023 | -18.35% 1805/2656 |
4.94% 851/2280 |
-6.99% 1756/2385 |
-10.01% 1934/2515 |
-7.03% 2021/2655 |
| 2022 | -25.83% 1350/2207 |
-18.60% 1357/1919 |
7.94% 411/2016 |
-15.25% 1253/2113 |
-0.39% 1600/2208 |
| 2021 | 7.22% 502/1822 |
-2.35% 626/1255 |
12.92% 301/1330 |
-5.05% 769/1466 |
2.40% 604/1822 |
| 2020 | - - |
- - |
- - |
7.87% 756/1164 |
11.19% 559/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南华中证杭州湾区ETF联接A VS. 长安沪深300非周期A(740101) |